A Phase II Study of Carboplatin, Cisplatin, Interferon-a, and Tamoxifen for Patients with Metastatic Melanoma

References

• Balch C M, Houghton A, Peters L. Cutaneous Melanoma. Cancer: Principles and Practice of Oncology, V T DeVita, S Hellman, S A Rosenberg. JB Lippincott. 1989; 1499–1542
   Google Scholar
• Del Prete S A, Maurer L H, O'Donnell J, et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984; 68: 1403–1405
   PubMedGoogle Scholar
• Walsh C, Speyer J, Wernz J, et al. Phase I study of the combination of alpha 2 interferon and cisplatinum. J Biol Response Mod 1989; 8: 11–15
   PubMedGoogle Scholar
• Margolin K, Doroshaw S, Akman L, et al. Treatment of advanced melanoma with cisdiamminedichloroplatinum and alpha interferon. Proc Am Soc Clin Oncol 1990; 9: A1074
   Google Scholar
• Bowman A, Fergusson S G, Allan M E, et al. Potentiation of cisplatin by alpha interferon in advanced non-small-cell lung cancer: A phase II study. Ann Oncol 1990; 1: 351–353
   PubMed Web of Science ®Google Scholar
• Welander C, Morgan T, Homesley H, et al. Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay. Int J Cancer 1985; 35: 721–729
   PubMed Web of Science ®Google Scholar
• Aapro M, Alberts D, Salmon S. Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 1983; 10: 161–166
   PubMed Web of Science ®Google Scholar
• Carmichael J, Fergusson R, Wolf C, et al. Augmentation of cytotoxicity of chemotherapy by human alpha interferons in human non-small cell lung cancer xenografts. Cancer Res 1986; 46: 4916–4920
   PubMed Web of Science ®Google Scholar
• Sklarin N T, Chahinian A P, Fever E S, et al. Augmentation of activity of cis-diamminedicWoroplatinum (II) and mitomycin-C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 1988; 48: 64–67
   PubMed Web of Science ®Google Scholar
• Corgoni G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327: 516–523
   PubMed Web of Science ®Google Scholar
• Chary K K, Higby D J, Henderson E S, et al. Phase I study of high dose cis-dichlorodiamrnineplatinum (II) with forced diuresis. Cancer Treat Rep 1977; 61: 367–370
   PubMedGoogle Scholar
• Kirkwood J M, Ernstoff M S, Davis C A, et al. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985; 103: 32–36
   PubMed Web of Science ®Google Scholar
• McClay E F, Mastrangelo M J, Bellet R, et al. An effective chemo/hormonal therapy regimen for the treatment of disseminated malignant melanoma. Update I. Proc Am Soc Clin Oncol 1989; 9: A1098
   Google Scholar
• McClay E F, Mastrangelo M J, Sprandio J D, et al. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989; 63: 1292–1295
   PubMed Web of Science ®Google Scholar
• Greenberg D A, Carpenter C L, Messing R O. Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC 12 neurosecretory cell line. Cancer Res 1987; 47: 70–74
   PubMed Web of Science ®Google Scholar
• Onoda J, Jacobs J, Taylor J, et al. Cisplatin and nifedipine: Synergistic cytotoxicity against murine solid tumors and their metastases. Cancer Lett 1986; 30: 181–188
   PubMed Web of Science ®Google Scholar
• Mowshowitz S L, Chin-Bow S T, Smith G D. Interferon and cis-DDP: combination chemotherapy for P388 leukemia in CDF mice. J Interferon Res 1982; 2: 587–591
   PubMedGoogle Scholar
• Gundagni F, Schlom J, Johnston W W, et al. Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 1989; 81: 502–511
   PubMed Web of Science ®Google Scholar
• Barker G M, Wiltshaw E. Use of high dose cisdichloradiammine platinum (II) following failure on previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Gynaecol 1981; 88: 1192–1199
   PubMedGoogle Scholar
• Luger S M, Kirkwood J M, Ernstoff M S, et al. High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst 1990; 82: 1934–1937
   PubMed Web of Science ®Google Scholar
• Mortimer J E, Schulman S, MacDonald J S, et al. High-dose cisplatin in disseminated melanoma: A comparison of two schedules. Cancer Chemother Pharmacol 1990; 25: 373–376
   PubMed Web of Science ®Google Scholar
• Glover D, Glick J, Weiler C, et al. WR-2721 and high dose cisplatin: An active combination in the treatment of melanoma. J Clin Oncol 1987; 5: 574–578
   PubMed Web of Science ®Google Scholar
• Portlock C, Murren J, Buzaid A, et al. High dose cisplatin and dacarbazine in metastatic melanoma. Proc Am Soc Clin Oncol 1989; 8: 284
   Google Scholar
• Murren J R, DeRosa W, Portlock C S, et al. High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 1991; 15: 67, 1514–1517
   Google Scholar
• Steffens T A, Bajorin D F, Oettgen H F, et al. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. Cancer 1991; 15: 68.1230–1237
   Google Scholar
• Casper E S, Bajorin D. Phase II trial of carboplatin in patients with advanced melanoma. Invest New Drugs 1990; 8: 187–190
   PubMed Web of Science ®Google Scholar
• Trump D L, Grem J L, Tutsch K O, et al. Platinum analogue combination chemotherapy: cisplatin and carboplatin–A phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J Clin Oncol 1987; 5: 1281–1289
   PubMed Web of Science ®Google Scholar
• Sznol M, Steis R G, Smith J W, et al. Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II study. Online J Curr Clin Trials 1992; 9
   Google Scholar